Genelux Corp. (GNLX)
2.24
+0.24
(+12.00%)
USD |
NASDAQ |
Nov 18, 16:00
2.24
0.00 (0.00%)
After-Hours: 19:20
Genelux Debt to Equity Ratio : 0.2554 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.2554 |
| June 30, 2026 | 0.1502 |
| March 31, 2026 | 0.1089 |
| December 31, 2025 | 0.146 |
| September 30, 2025 | 0.0874 |
| June 30, 2025 | 0.0714 |
| March 31, 2025 | 0.0599 |
| December 31, 2024 | 0.0711 |
| September 30, 2024 | 0.0616 |
| June 30, 2024 | 0.0586 |
| March 31, 2024 | 0.1572 |
| December 31, 2023 | 0.1294 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.0789 |
| June 30, 2023 | 0.0844 |
| March 31, 2023 | 1.343 |
| December 31, 2022 | -0.7365 |
| September 30, 2022 | -0.7862 |
| June 30, 2022 | -0.652 |
| March 31, 2022 | -0.6883 |
| December 31, 2021 | -0.7644 |
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | -1.029 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.0518 |
| Alnylam Pharmaceuticals, Inc. | 0.8316 |
| Anika Therapeutics, Inc. | 0.1901 |
| Savara, Inc. | 0.2815 |
| Arrowhead Pharmaceuticals, Inc. | 27.84 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 20.61M |
| Total Liabilities (Quarterly) | 11.43M |
| Shareholders Equity (Quarterly) | 9.178M |
| Current Ratio | 1.162 |
| Net Debt Paydown Yield | -0.11% |